considerations when developing longcovid therapeutics
Published 2 years ago • 1.4K plays • Length 26:32Download video MP4
Download video MP3
Similar videos
-
49:07
interview with dr. james heath: multiple early factors that anticipate longcovid
-
30:31
dr. amy proal: presentation at the 1st polybio seminar series
-
5:55:29
polybio research foundation spring 2024 symposium
-
48:25
interview with dr. david putrino: treatment/research at mt. sinai's longcovid (post-covid) clinic.
-
1:02:27
what longcovid may be and how to study it
-
38:25
interview with dr. lena pernas: possible toxoplasma reactivation in covid-19/longcovid
-
1:21:34
the latest on long covid research with amy proal
-
48:26
interview with dr. michael peluso: clinical research infrastructure innovation for longcovid/pasc
-
0:49
clues about the cause of long covid? #shorts
-
46:14
interview with dr. sara cherry: tissue models of sars-cov-2 persistence and antiviral activity
-
42:26
interview with dr. akiko iwasaki: an overview of her research on longcovid and me/cfs
-
44:30
how environmental factors may impact vagus nerve/brainstem/neuroinflammation in me/cfs and longcovid
-
0:43
inflammation in the brain after covid-19 | dr. daniel amen
-
4:30:44
polybio research foundation fall symposium
-
0:59
linking me/cfs and long covid
-
1:40:08
long covid conference - session 5 - research towards treatment of long covid
-
59:54
the gic – slci program series: long covid research, policy & economic impact session i
-
1:01:13
ask the expert webinar: long covid